{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-25-000120","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.594884+00:00","generated_at":"2026-05-17T00:41:29.133787+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tarsus Q3 2025: XDEMVY sales $118.7M, +147% YoY; net loss narrows to $0.30/share","bullets":["XDEMVY net sales of $118.7M (Q3 2024: $48.1M); >103,000 bottles delivered to patients.","Net loss of $12.6M vs $23.4M; diluted EPS $(0.30) vs $(0.61) in prior-year quarter.","Cash, equivalents & marketable securities of $401.8M as of Sept 30, 2025.","Phase 2 trial of TP-04 for ocular rosacea starting Dec 2025; Phase 2 of TP-05 for Lyme disease in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-25-000120","json":"https://secwatch.observer/filing/0001819790-25-000120.json","markdown":"https://secwatch.observer/filing/0001819790-25-000120.md","text":"https://secwatch.observer/filing/0001819790-25-000120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000120/0001819790-25-000120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000120/tars-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:41:29.133787+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}